approximately 15,000 deaths in USA annually [5] . Therefore, identification of protective factors and possible agents associated with increased survival can have great implications. Statin's role in ovarian cancer has been controversial with varying opinions. In order to collect all the evidence, we conducted a literature search utilizing Medline (PubMed and Ovid) and Cochrane Library to identify studies related to statins effect on incidence and survival in ovarian cancer. Eight relevant citations were found and are summarized in Table 1 .
Only three studies [6] [7] [8] were found which reported the effect of statin therapy on ovarian cancer survival while the others [9] [10] [11] [12] [13] only reported risk of ovarian cancer.
Habis et al. [6] reported a decrease in hazards of diseasespecific death (adjusted hazard ratio, 0.23; p=0.04) among statin users in non-serous papillary epithelial ovarian cancer. Similarly Elmore et al. [7] showed significantly longer survival in statin users (62 months) compared with non-users (46 months, p=0.04). Out of the six studies [8] [9] [10] [11] [12] [13] reporting risk of ovarian cancer, only one found a significant reduction in ovarian cancer incidence with statin usage. Baandrup et al. [9] documented a decrease risk only with respect to mucinous ovarian cancer enforcing the need for further subgroup analysis. When findings of five studies [8, [10] [11] [12] [13] In conclusion, we suggest that statins impact on ovarian cancer warrants further investigation with larger randomized controlled trials as observational studies are subject to bias and may lead to false slight benefits. Effect of statins with respect to different histological subtypes also need to be further studied.
